Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health
Post Content
Eli Lilly becomes first pharma firm to join $1 trillion club – Al Jazeera
Eli Lilly becomes first pharma firm to join $1 trillion club Al Jazeera Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value The New York Times Eli Lilly hits $1 trillion market value, a first for a health-care company CNBC Is GLP-1 the new AI? Drugmaker Eli Lilly joins the $1 trillion market-cap club. MarketWatch […]
Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s why
The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars.
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1
Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club – Investor’s Business Daily
Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club Investor’s Business Daily Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value The New York Times Is GLP-1 the new AI? Drugmaker Eli Lilly joins the $1 trillion market-cap club. MarketWatch Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts Yahoo […]
Cardiovascular benefits of GLP-1 drugs independent of weight loss
Revising our earlier interpretation of SELECT trial data in light of new analyses The post Cardiovascular benefits of GLP-1 drugs independent of weight loss appeared first on Peter Attia.
How Bioethics and Reproductive Justice Ought to Inform Glucagon‐Like Peptide‐1 Receptor Agonists, Research, and Pregnancy
ABSTRACT There are large evidence gaps for pregnant people, and research in pregnancy should be prioritized to ensure strong evidence to guide safe clinical practice. GLP-1 receptor agonist (GLP-1RA) research is a modern example that shows how pregnancy continues to preclude individuals from participating in and subsequently receiving potential benefits of research or understanding their […]
Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand
Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more than 35% rally in the company’s stock this year has largely been driven by the explosive growth of the weight-loss drug […]
Eli Lilly hits $1 trillion market value, a first for a health-care company
Eli Lilly reached a $1 trillion market capitalization on Friday, the first health-care company in the world to join the exclusive club dominated by tech firms. Eli Lilly briefly hit the $1 trillion mark in morning trading before retreating. It was last trading around $1,048 a share. The company’s stock has climbed more than 36% […]
New evidence shows tirzepatide and semaglutide strongly protect the heart
A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs.